at9283
Small moleculeexperimental
Clinical trial activity
5 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00522990)
Timeline
Indications
Studied for
- Leukemia · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Primary Myelofibrosis · Phase 1/Phase 2
Mechanism of action
FLT3 inhibitor
- Tyrosine-protein kinase ABLINHIBITOR
ABL1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
AURKA inhibitor
AURKB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1- Mol. weight
- 381.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL495727 ↗
Also known as
- 1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-pyrazol-4-yl)urea
- at9283
- at9283
- at9283
- at9283
- at 9283
- at-9283
- at-9283
- at-9283
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01431664 | Phase 1 | Sep 1, 2011 | Cancer Research UK, University of Melbourne |
| NCT01145989 | Phase 2 | Jun 1, 2010 | Canadian Cancer Trials Group, Horizon Health Network |
| NCT00985868 | Phase 1 | Sep 1, 2009 | Cancer Research UK, Royal Marsden Hospital NHS Trust |
| NCT00443976 | Phase 1 | Jan 1, 2007 | British Columbia Cancer Agency, Canadian Cancer Trials Group, University of Ottawa |
| NCT00522990 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2006 | Astex Pharmaceuticals, Inc., University of Texas at Houston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Cancer Research UK | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Astex Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2006 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Horizon Health Network | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
9 organizations
Page 1 / 1